TG Therapeutics | TGTX - Ordinary Share Capital


TG Therapeutics reported $153.08M in Ordinary Share Capital for its fiscal quarter ending in June of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Alaunos Therapeutics USD 2.38M 172K Mar/2026
Amgen USD 541M 1000K Jun/2026
Ardelyx USD 246.97M 2.62M Mar/2026
Arrowhead Research USD 141.14M 564K Jun/2026
Bayer EUR 982.42M 0 Jun/2026
Biogen USD 146.7M 200K Sep/2025
Corcept Therapeutics USD 107.33M 1.36M Mar/2026
Curis USD 2M 10.93M Mar/2026
Gilead Sciences USD 1.24B 1000K Jun/2026
J&J USD 2.41B 1.35M Mar/2026
Karyopharm Therapeutics USD 22.54M 4.23M Mar/2026
Novartis USD 1.9B 7.38M Jun/2026
Novavax USD 162.58M 106K Dec/2025
PTC Therapeutics USD 82.88M 1.41M Mar/2026
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
TG Therapeutics USD 153.08M 2.23M Jun/2026
Verastem USD 87.84M 10.1M Mar/2026
Vertex Pharmaceuticals USD 253.3M 900K Jun/2026